[Molecular bases of the treatment of Lesch-Nyhan syndrome, related syndromes and common gout].
D000227:Adenine Nucleotides; D000493:Allopurinol / Q000627:therapeutic use; D005246:Feedback; D006073:Gout / Q000188:drug therapy* / Q000201:enzymology; D006151:Guanosine; D006801:Humans; D007042:Hypoxanthines; D007926:Lesch-Nyhan Syndrome / Q000188:drug therapy* / Q000201:enzymology; D009963:Orotic Acid / Q000627:therapeutic use; D010430:Pentosyltransferases / Q000378:metabolism*; D011720:Pyrazoles; D011743:Pyrimidines / Q000627:therapeutic use; D013438:Sulfhydryl Compounds; D014527:Uric Acid / Q000378:metabolism; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D000227:Adenine Nucleotides; D007042:Hypoxanthines; D011720:Pyrazoles; D011743:Pyrimidines; D013438:Sulfhydryl Compounds; D006151:Guanosine; D014527:Uric Acid; D009963:Orotic Acid; D000493:Allopurinol; D014969:Xanthine Oxidase; D010430:Pentosyltransferases
Bases moléculaires du traitement du syndrome de Lesch-Nyhan, des syndromes apparentés et de la goutte commune.